Teva Pharmaceutical Industries Limited (TEVA) Q3 2025 Earnings Call TranscriptSeeking Alpha • 11/05/25
Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit OutlookBenzinga • 11/05/25
Here's What Key Metrics Tell Us About Teva Pharmaceutical Industries (TEVA) Q3 EarningsZacks Investment Research • 11/05/25
Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPSGlobeNewsWire • 11/05/25
Seeking Clues to Teva Pharmaceutical Industries (TEVA) Q3 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 11/04/25
Here's Why This Israeli Investment Giant Is Betting $834 Million on Teva StockThe Motley Fool • 11/03/25
Teva to Present at UBS Global Healthcare Conference and Jefferies London Healthcare Conference in NovemberGlobeNewsWire • 10/31/25
All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to BuyZacks Investment Research • 10/21/25
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?Zacks Investment Research • 10/21/25
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?Zacks Investment Research • 10/21/25
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in EuropeGlobeNewsWire • 10/20/25
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I DisorderZacks Investment Research • 10/13/25
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026The Motley Fool • 10/13/25
FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I DisorderGlobeNewsWire • 10/10/25
Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight QuartersThe Motley Fool • 10/06/25